| 产品名称 | Peptides EP11322_1 | Influenza A M1 59-68 (HLA-A*02:01) |
|---|---|
| 目录号 | EP11322_1 |
| 别名 | Influenza A M1 59-68 (HLA-A*02:01) |
| 外观 | 见COA |
| 分子量 | N/A |
| CAS | N/A |
| 溶解度 | |
| 存储条件 | 见COA |
| 保存时间 | 见COA |
| 备注1 | |
| 备注2 |
| 目录号 | 规格 | 价格 | 库存状态 | |
| EP11322_1 | 1 mg; 5 mg | 咨询 | 咨询 |
Peptides EP11322_1 | Influenza A M1 59-68 (HLA-A*02:01)
品名：Influenza A M1 59-68 (HLA-A*02:01)
货号：EP11322_1
规格：1 mg; 5 mg
品牌：Peptides.de
产品描述
The ILGFVFTLTV peptide (epitope ID 27066) overlaps with the well-known immunodominant epitope GILGFVFTL from Influenza A Matrix Protein 1 (M1; UniProt:P03485). Influenza A MP 59-68 is used for the development of more broadly protective influenza vaccines and as a control peptide in immunological studies.Researchers investigated the immunogenicity and protective efficacy of Modified Vaccinia Virus Ankara (MVA) vectors encoding internal influenza antigens in HLA-A2.1 transgenic mice. Following vaccination with recombinant MVAs expressing peptides derived from Influenza A Matrix Protein 1 (M1), the induced CD8⁺ T cell responses were primarily directed against the immunodominant epitope M1 58-66. However, consistent T cell responses were also observed against the overlapping peptide M1 59-68. CD8⁺ T cell activity was assessed using an IFN-γ ELISPOT assay.
| Protein | Matrix protein |
| Species | Influenza virus |
| Application | T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response |
| Indication | Infectious disease |
